Curriculum Vitae

Last name, First name: **Vanhaecke Tamara** **Gender**: **Female**

Nationality: Belgian

Overall Scientific Expertise:
[Based on your educational and professional backgrounds, please summarise (up to 100 words) your scientific expertise (disciplinary areas, competencies, etc.) especially your health and environmental risk assessment expertise *(if applicable*).]

She is workleader of the research unit *In Vitro* Toxicology and Dermato-Cosmetology at the Vrije Universiteit Brussel (VUB) and has experience in basic *in vitro* toxicological research, i.e. the development of *in vitro* 3R alternative methods important for safety testing of new and existing molecules. She has > 120 publications in the area of (*in vitro*) toxicology in peer-reviewed journals. She is an European Registered Toxicologist with experience in risk assessment of cosmetic ingredients and finished products. She is involved in a yearly organized one-week course at the VUB with respect to the safety assessment of cosmetics in the EU.

Professional Experience
[Starting with your present occupation, list in reverse chronological order each activity in which you have been engaged. Please copy and paste more rows if needed.]

Years employed from – to	Title of position	Employer – name and location	Areas of professional specialisation♠
2013 - now	Full-time Professor at Dept of *In Vitro* Toxicology and Dermato-Cosmetology	Vrije Universiteit Brussel, BE	Research on 3R-alternatives Risk assessment of cosmetics
2010 - 2013	Full-time Head docent at Dept of Toxicology and Dermato-Cosmetology	Vrije Universiteit Brussel, BE	Research on 3R-alternatives Risk assessment of cosmetics
2000 - 2010	Post-doc at Dept of Toxicology and Dermato-Cosmetology	Vrije Universiteit Brussel, BE	Research on 3R-alternatives Risk assessment of cosmetics
1994 - 2000	Assistant at Dept of Toxicology and Dermato-Cosmetology	Vrije Universiteit Brussel, BE	Research on 3R-alternatives

♠[*For example*: toxicology (alternative methods, carcinogenesis, endocrine, immunotoxicity, occupational, exposure assessment, genotoxicity, etc.), chemistry (atmospheric, medicinal, peptide, etc.), physics (biophysics, EMF radiation, noise, etc.), engineering (genetic, environmental, medical, etc.), biology (antimicrobial resistance, biophysics, biotechnology, etc.), medicine (allergies, neurology, etc.), epidemiology (clinical, genetic, cancer, etc.) environmental science (air quality, waste treatment, climate change, ecology, etc.), biostatistics, pharmacokinetics, medical technologies, nanoscience, etc…]

Educational Background

[Starting with the most recent, please provide the details of your post-secondary education and/or professional training (e.g. university or its equivalent, postgraduate, postdoctoral). Please copy and paste more rows if needed.]

Year	Degree awarded	Educational Institution – name and location	Areas of educational specialisation*
2004	Certificate	Vrije Universiteit Brussel, BE	Safety Assessment of Cosmetics in the EU
1994 - 2000	Doctor in Pharmaceutical Sciences	Vrije Universiteit Brussel, BE	*In Vitro* Toxicology
1992-1994	Master in Bio-Engineering in Cell- and Gene-Biotechnology	Vrije Universiteit Brussel, BE	Bio-engineering
1990-1992	Bachelor in Bio-Engineering in Cell- and Gene-Biotechnology	Vrije Universiteit Brussel, BE	Bio-engineering

*[*For example*: chemistry (analytical, organic, etc.), physics (thermodynamics, nuclear, etc.), engineering (mechanical, electrical, chemical, civil, etc.), biology (microbiology, molecular, etc.), medicine (dermatology, oncology, etc.), environmental science, pharmacology, toxicology, etc.…]

Memberships in Scientific Advisory Bodies/Committees/Panels *(if any)***:**

- Invited Expert Toxicologist for the Hoge GezondheidsRaad (Federal Government Belgium) since January 2003.
- Member of the organizing committee of the Matchmaking Event 'New scientific impulses towards 3R alternatives – Methods to replace, reduce and refine animal use', an initiative of Technology Transfer Interface, VUB.
- Nominated expert for ECHA (European Chemicals Agency).
- Member of the Pool of Scientific Advisors on Risk Assessment set up by the European Commission (2008/721/EC) since March 2009.
- Member of the ECVAM Validation Management Group – International validation study in the field of Toxicokinetics and Metabolism: Human HepaRG and cryopreserved hepatocytes CYP induction test methods.
- Member of the panel Pharmaceutical sciences and protein chemistry of the fund of Scientific research Flanders (FWO Med1 commission) since October 2010.
- European registered Toxicologist (ERT, Belgian Register)
- Invited expert for IWT (Agency for Innovation by Science and Technology in Flanders) to select PhD candidates in November 2011 & 2012, and post doctoral innovation mandates in November 2014.
- Member of the Federal Ethical Committee on the protection of Animals since January 2013.
- Invited expert of the Scientific Committee on Consumer Safety (SCCS, under DG SANTE) from March 2014 till April 2016, elected member of SCCS since April 2016.

Memberships in Learned Societies *(if any)*:
- Member of BCLAS (Belgian Council for Laboratory Animal Science)
- Member of BELTOX (the Belgian Society of Toxicology)
- Member of ESTIV (European Society of In Vitro Toxicology)
- Member of European consensus platform for alternatives (*ecopa)*
- Member of the International Society for In Vitro Methods (INVITROM), Vice chair and secretary since 2011 and 2014, respectively.

Memberships in Editorial Boards *(if any)*:

None.

List of Publications:
[Please indicate the type and total number of your publications. In addition, provide the bibliographic details for the 7 most representative, peer-reviewed articles which highlight the main areas of your scientific expertise.]

- > 120 scientific publications dealing with (*in vitro*) toxicology in peer-reviewed journals
- 25 book chapters dealing with 3R-alternative methods

1. Elaut G., Rogiers V. and Vanhaecke T. (2007) The pharmaceutical potential of histone deacetylase inhibitors, *Current Pharmaceutical Design* 13, 2584-2620. IF2007 = 4.868.
2. Snykers S., Henkens T., De Rop E., Vinken M., Fraczek J., De Kock J., De Prins E., Geerts A., Rogiers V. and Vanhaecke T. (2009) Role of epigenetics in liver-specific gene transcription, hepatocyte differentiation, and stem cell reprogrammation. *Journal of Hepatology* 51(1), 187-211. IF_{2009} = 7.818.
3. Snykers S., De Kock J., Rogiers V. and Vanhaecke T. (2009) In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art. *Stem Cells* 27(3), 577-605. IF_{2009} = 7.924.
4. Vanhaecke T., Pauwels M., Vinken M., Ceelen L. and Rogiers V. (2011) Towards an integrated in vitro strategy for repeated-dose toxicity testing. *Archives of Toxicology* 85, 365-366. IF_{2011} = 4.674.
5. Bolleyn J., De Kock J., Mertens H., Fraczek J., Vinken M., Govaere O., Roskams T., Rogiers V. and Vanhaecke T. (2012) Liver-specific miR-122 does not affect mRNA levels of cytochrome P450 enzymes and nuclear receptors in primary rat hepatocyte cultures. *ALTEX-Alternatives to Animal Experimentation* 1/12: 165-172. IF_{2012} = 4.093.
6. Bolleyn J., De Kock J., Rodrigues R.M., Vinken M., Rogiers V. and Vanhaecke T. (2015) MicroRNAs as key regulators of xenobiotic biotransformation and drug response. *Archives of Toxicology* 89(9): 1523-1541. IF_{2014} = 5.980.
7. Rodrigues R.M., Branson S., De Boe V., Sachinidis A., Rogiers V. De Kock J. and Vanhaecke T. (2015) In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic. *Archives of Toxicology* 90(3): 677-689. IF_{2014} = 5.980.